Show simple item record

Evaluación de costo-efectividad de la vacuna anti-rotavirus en Chile

Authordc.contributor.authorConstenla, Dagna 
Authordc.contributor.authorO'Ryan Gallardo, Miguel es_CL
Authordc.contributor.authorNavarrete, María S. es_CL
Authordc.contributor.authorAntil, Lynn es_CL
Authordc.contributor.authorRheingans, Richard D. es_CL
Admission datedc.date.accessioned2008-11-28T09:06:30Z
Available datedc.date.available2008-11-28T09:06:30Z
Publication datedc.date.issued2006
Cita de ítemdc.identifier.citationRev Méd Chile 2006; 134: 679-688en
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/127571
Abstractdc.description.abstractBackground: Cost effectiveness studies are essential to assess the real value of interventions with preventive or therapeutic objectives. Aim: To assess the theoretical costeffectiveness of a vaccine against rotavirus in Chilean children of less than five years of age. Material and methods: An economic model was developed based on information on disease incidence, health care costs associated with treatment and the effectiveness and costs of vaccination. Net disease and vaccination costs were estimated from the health system perspective and were compared with life years and disability-adjusted life-years (DALYs) gained using a 3% discount rate. Local administrative and accounting hospital data and vaccine efficacy data were used to estimate healthcare costs and cost-effectiveness of vaccination. Results: A rotavirus vaccination program would prevent 10 deaths due to rotavirus gastroenteritis, 6,245 related hospitalizations and 41,962 outpatient visits during the first five years of life, per vaccinated cohort. For every 1,000 children born, the healthcare service spends US$15,077 on treatment of gastroenteritis. From the healthcare perspective, vaccination would yield a cost-effectiveness ratio of US$11,261 per DALY when the price of the vaccine is US$24 per course. Conclusions: Rotavirus vaccine can effectively reduce the disease burden and healthcare costs of rotavirus gastroenteritis and can be a cost-effective investment compared to other options.en
Patrocinadordc.description.sponsorshipPatrocinio de GlaxoSmithKline Biologicals.en
Lenguagedc.language.isoesen
Keywordsdc.subjectCost-benefit analysisen
Títulodc.titleEvaluación de costo-efectividad de la vacuna anti-rotavirus en Chileen
Title in another languagedc.title.alternativePotential cost effectiveness of a rotavirus vaccine in Chileen
Document typedc.typeArtículo de revistaen


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record